Bortezomib inhibits human osteoclastogenesis

Osteoclast differentiation and activation

2003 • 6,172 citations

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

1997 • 5,058 citations

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1998 • 4,184 citations

Bone Resorption by Osteoclasts

2000 • 3,797 citations

Metastasis to bone: causes, consequences and therapeutic opportunities

2002 • 2,661 citations

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1997 • 2,257 citations

Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families

1999 • 2,238 citations

IκB: a Specific Inhibitor of the NF-κB Transcription Factor

1988 • 2,203 citations

The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB

1994 • 2,124 citations

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1999 • 1,621 citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 • 1,520 citations

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 • 1,447 citations

The IKK NF-κB system: a treasure trove for drug development

2004 • 1,340 citations

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

1999 • 1,267 citations

c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling

1994 • 1,253 citations

Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesisin Vitro¹

1998 • 1,211 citations

TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells

1997 • 1,054 citations

NF-κB as a Therapeutic Target in Multiple Myeloma

2002 • 906 citations

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

1999 • 779 citations

RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis

1998 • 729 citations

A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.

1994 • 723 citations

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

2003 • 572 citations

Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)

2000 • 511 citations

Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome)

1988 • 404 citations

Degradation of nuclear oncoproteins by the ubiquitin system in vitro.

1991 • 345 citations

Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts

2000 • 345 citations

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

2004 • 335 citations

The Mouse Gene for Vascular Endothelial Growth Factor

1996 • 335 citations

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

2004 • 319 citations

Fracture Risk With Multiple Myeloma: A Population-Based Study

2005 • 312 citations

Multiple myeloma bone disease: pathophysiology of osteoblast inhibition

2006 • 299 citations

RANK ligand and osteoprotegerin in myeloma bone disease

2003 • 260 citations

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

2006 • 218 citations

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.

2003 • 216 citations

Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

2003 • 214 citations

Receptor activator of nuclear factor-κB ligand and osteoprotegerin

2001 • 191 citations

Cancer and the Microenvironment

2004 • 188 citations

Degradation of the Proto-Oncogene Product c-Fos by the Ubiquitin Proteolytic System In Vivo and In Vitro: Identification and Characterization of the Conjugating Enzymes

1995 • 167 citations

JunB can substitute for Jun in mouse development and cell proliferation

2002 • 156 citations

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

2003 • 156 citations

Expression of VEGF and its receptors by myeloma cells

2003 • 146 citations

The IκB Kinase Complex and NF-κB Actas Master Regulators of Lipopolysaccharide-Induced Gene Expressionand Control Subordinate Activation ofAP-1

2004 • 145 citations

Proteasome inhibitor PS‐341 induces growth arrest and apoptosis of non‐small cell lung cancer cells via the JNK/c‐Jun/AP‐1 signaling

2004 • 133 citations

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

2006 • 128 citations

p38 Mitogen-Activated Protein Kinase Is Crucially Involved in Osteoclast Differentiation But Not in Cytokine Production, Phagocytosis, or Dendritic Cell Differentiation of Bone Marrow Macrophages

2003 • 87 citations

RANKing c-Jun in osteoclast development

2004 • 82 citations

Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines

2003 • 76 citations

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

2005 • 72 citations

Proteasome as an Emerging Therapeutic Target in Cancer

2007 • 64 citations

New insights into the pathophysiology and management of bone disease in multiple myeloma

2003 • 57 citations

Regulation of c-Jun Phosphorylation by the IκB Kinase-ε Complex in Fibroblast-Like Synoviocytes

2005 • 49 citations

Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system

1992 • 26 citations